{
    "clinical_study": {
        "@rank": "73850", 
        "acronym": "CAPITL", 
        "arm_group": {
            "arm_group_label": "Combined drug approach, safety study", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to establish the safety of the combined drug approach\n      (anti-thrombin III, infliximab, apotransferrin, human recombinant erythropoietin beta,\n      C1-inhibitor, glutathione, alfa-tocopherol, melatonin and epoprostenol)aimed to reduce\n      ischemia-reperfusion injury during liver transplantation in eligible recipients."
        }, 
        "brief_title": "Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers", 
        "condition": "Reperfusion Injury", 
        "condition_browse": {
            "mesh_term": [
                "Ischemia", 
                "Reperfusion Injury", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients suffering from irreversible liver failure eligible for liver transplantation\n             according to Eurotransplant guidelines.\n\n          2. Patients > 18 years of age at time of listing on Eurotransplant waiting list for\n             liver transplantation in University Hospitals Leuven, Belgium.\n\n        Exclusion Criteria:\n\n          1. Patients who refuse to participate in the study.\n\n          2. History of hypersensitivity to one/several component(s) of the combined drug\n             approach.\n\n          3. Conditions that prevent the use of the combined drug approach:\n\n               -  Administration of heparin at therapeutic dose pre-operatively,\n\n               -  Congestive heart failure,\n\n               -  Pre-operative level of hemoglobin higher than 13 mg/dl,\n\n               -  History of seizure, poorly controlled arterial hypertension, myocardial\n                  infarction or stroke in the month preceding the liver transplantation, venous\n                  thromboembolic disease,\n\n               -  Unstable angina pectoris,\n\n               -  Sepsis, abcesses or opportunistic infections,\n\n               -  History of infliximab treatment,\n\n               -  Use of vitamin K antagonist anticoagulation.\n\n          4. Mental conditions rendering the subject incapable to understand the nature, scope,\n             and consequences of the trial.\n\n          5. Combined organ transplantation.\n\n          6. Re-transplantation.\n\n          7. Patients that are dialysis-dependent prior to the liver transplantation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01886443", 
            "org_study_id": "CAPITL safety"
        }, 
        "intervention": [
            {
                "arm_group_label": "Combined drug approach, safety study", 
                "intervention_name": "Antithrombin-III", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Combined drug approach, safety study", 
                "intervention_name": "Infliximab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Combined drug approach, safety study", 
                "intervention_name": "Apotransferrin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Combined drug approach, safety study", 
                "intervention_name": "Human recombinant erythropoietin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Combined drug approach, safety study", 
                "intervention_name": "C1-Inhibitor", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Combined drug approach, safety study", 
                "intervention_name": "Glutathione", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Combined drug approach, safety study", 
                "intervention_name": "Alfa-tocopherol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Combined drug approach, safety study", 
                "intervention_name": "Melatonin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Combined drug approach, safety study", 
                "intervention_name": "Epoprostenol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antithrombins", 
                "Antithrombin III", 
                "Antithrombin Proteins", 
                "Epoetin Alfa", 
                "Epoprostenol", 
                "Melatonin", 
                "Tocopherols", 
                "Vitamin E", 
                "Alpha-Tocopherol", 
                "Tezosentan", 
                "Infliximab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Liver", 
            "Transplantation", 
            "Ischemia-reperfusion", 
            "Safety"
        ], 
        "lastchanged_date": "September 9, 2013", 
        "location": {
            "contact": {
                "email": "Nicolas.Meurisse@med.kuleuven.be", 
                "last_name": "Nicolas Meurisse, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Leuven", 
                    "country": "Belgium", 
                    "zip": "3000"
                }, 
                "name": "University Hospitals Leuven"
            }, 
            "investigator": [
                {
                    "last_name": "Diethard Monbaliu, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jacques Pirenne, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Nicolas Meurisse, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1 Safety Study of Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers", 
        "overall_contact": {
            "email": "diethard.monbaliu@uzleuven.be", 
            "last_name": "Diethard Monbaliu, MD, PhD"
        }, 
        "overall_contact_backup": {
            "email": "Nicolas.Meurisse@med.kuleuven.be", 
            "last_name": "Nicolas Meurisse, MD"
        }, 
        "overall_official": {
            "affiliation": "Abdominal transplant surgery - transplant coordination, Abdominal transplant surgery lab (microbiology & immunology Dpt)", 
            "last_name": "Diethard Monbaliu, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "During and within the 7 days following the liver transplantation"
        }, 
        "reference": [
            {
                "PMID": "19826248", 
                "citation": "Monbaliu D, Vekemans K, Hoekstra H, Vaahtera L, Libbrecht L, Derveaux K, Parkkinen J, Liu Q, Heedfeld V, Wylin T, Deckx H, Zeegers M, Balligand E, Buurman W, van Pelt J, Porte RJ, Pirenne J. Multifactorial biological modulation of warm ischemia reperfusion injury in liver transplantation from non-heart-beating donors eliminates primary nonfunction and reduces bile salt toxicity. Ann Surg. 2009 Nov;250(5):808-17. doi: 10.1097/SLA.0b013e3181bdd787."
            }, 
            {
                "PMID": "21987442", 
                "citation": "Vekemans K, Monbaliu D, Balligand E, Heedfeld V, Jochmans I, Pirenne J, van Pelt J. Improving the function of liver grafts exposed to warm ischemia by the Leuven drug protocol: exploring the molecular basis by microarray. Liver Transpl. 2012 Feb;18(2):206-18. doi: 10.1002/lt.22446."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01886443"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Universitaire Ziekenhuizen Leuven", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universitaire Ziekenhuizen Leuven", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}